Today, Google announced the launch of Calico, a new company that will "focus on health and well-being, in particular the challenge of aging and associated diseases."
Former Genentech CEO Arthur D. Levinson, who is Chairman of the Board at both Genentech and Apple, is CEO and a founding investor of the new Google spinoff venture.
Noted Google+ user Larry Page posts this morning:
OK … so you’re probably thinking wow! That’s a lot different from what Google does today. And you’re right. But as we explained in our first letter to shareholders, there’s tremendous potential for technology more generally to improve people’s lives. So don’t be surprised if we invest in projects that seem strange or speculative compared with our existing Internet businesses. And please remember that new investments like this are very small by comparison to our core business. Art and I are excited about tackling aging and illness. These issues affect us all—from the decreased mobility and mental agility that comes with age, to life-threatening diseases that exact a terrible physical and emotional toll on individuals and families. And while this is clearly a longer-term bet, we believe we can make good progress within reasonable timescales with the right goals and the right people.Hey, none of this health and wellness stuff should come as a surprise to internet old-timers who recall when the "web crawler" was named "BackRub."
The American Quarter Horse Association has been ordered to accept cloned horses into its registry by a jury in the courtoom of U.S. District Court Judge Mary Lou Robinson. They were sued by a pair of Texas breeders, who said the organization's practice of excluding cloned horses was monopolistic. The judge did rule on awarding costs to the breeders, who spent some $900,000 on the case. Read the rest
Pseudopterosins are a family of naturally occurring chemicals with the power to reduce inflammation, skin irritation, and pain. In other words, they make a great additive in skin cream. If you want skin that less red, pseudopterosins can help. Want a lotion that soothes your face after a particularly vigorous round of exfoliation? Call on pseudopterosins.
Pseudopterosins come from a coral called Pseudopterogorgia elisabethae. That's it in the photo above. For years, researchers and pharmaceutical companies thought they were sustainably harvesting P. elisabethae because, instead of simply gathering any of the coral they could find, they merely pruned it — leaving plenty of the creature to grow back.
But, it turns out that this is a really good example of a frustrating problem — what seems sustainable is not always actually sustainable. Doing the right thing, environmentally speaking, isn't as intuitive as we'd like it to be. (Also, pruning an animal isn't like pruning a plant.) At Deep Sea News, Dr. M explains:
Read the rest
After prunings in 2002 and 2005 and before the annual spawning, Christopher Page and Howard Lasker examined 24 pruned corals and 20 unpruned corals. What the researchers found is that although colonies appeared healthy pruned corals produced less eggs. ... Why would pruned corals produce less eggs and sperm? When organisms are injured more energy is diverted away from reproduction and toward repair. Interestingly, this pruning may actually also creating artificial selection. If workers are targeting larger and fuller corals to prune, then smaller less thick corals will be reproducing more and eventually become more dominant.
The Guerrilla Grafters are a group of rogue artists who roam San Francisco, covertly grafting fruit-tree branches onto ornamental trees to create a municipal free lunch. John Robb calls it "resilient disobedience."
How can you improve the productivity of your community even if the officials are against it?
One way is through resilient disobedience. For example, there’s a group of gardeners in San Francisco that are spreading organic graffiti across the city. How? By grafting branches from fruit trees onto ornamental trees that have been planted along sidewalks and in parks.
They are using a very simple tongue in groove splice that’s held together with annotated electrical tape. Good luck to them.
When you have been diagnosed with cancer, as I have, you quickly grow accustomed to "friendly cancer spam." Friends, relatives, and well-meaning acquaintances routinely forward you a gazillion identical links to whatever this week's hot cancer news headline may be.
So it was for me with this New York Times story on Lukas Wartman, a leukemia doctor and researcher at Washington University who developed leukemia. As he faced death last Fall, his cancer genome was sequenced by his colleagues.
What was revealed then led to a treatment plan that targeted the specifics of his genetic makeup. And so far, according to Gina Kolata's report, that experimental treatment plan has been an amazing success. Snip:
Read the rest
Dr. Ley’s team tried a type of analysis that they had never done before. They fully sequenced the genes of both his cancer cells and healthy cells for comparison, and at the same time analyzed his RNA, a close chemical cousin to DNA, for clues to what his genes were doing.
The researchers on the project put other work aside for weeks, running one of the university’s 26 sequencing machines and supercomputer around the clock. And they found a culprit — a normal gene that was in overdrive, churning out huge amounts of a protein that appeared to be spurring the cancer’s growth.
Even better, there was a promising new drug that might shut down the malfunctioning gene — a drug that had been tested and approved only for advanced kidney cancer. Dr. Wartman became the first person ever to take it for leukemia.
Here's an amazing feel-good video with which to end your week, via the National Science Foundation. The really awesome footage starts around a minute and a half in.
"James C. (Cole) Galloway, associate professor of physical therapy, and Sunil Agrawal, professor of mechanical engineering -- have outfitted kid-size robots to provide mobility to children who are unable to fully explore the world on their own."
The robotic assistance devices are designed to help infants whose mobility and independence is limited by conditions such as autism, spina bifida, muscular dystrophy, Down syndrome, and cerebral palsy.
There are over 1.3 trillion bricks manufactured each year worldwide, and over 10% are made by hand in coal-fired ovens. On average, the baking process emits 1.4 pounds of carbon per brick - more than the world's entire aviation fleet. In countries like India and China, outdated coal-fired brick kilns consume more energy, emit more carbon, and produce great quantities of particulate air pollution. Dosier's process replaces baking with simple mixing, and because it is low-tech (apart from the production of the bacterial activate), can be done onsite in localities without modern infrastructure. The process uses no heat at all:mixing sand and non-pathogenic bacteria (sporosar) and putting the mixture into molds. The bacteria induce calcite precipitation in the sand and yield bricks with sandstone-like properties. If biomanufactured bricks replaced each new brick on the planet, it would save nearly 800 million tons of CO2 annually.Biomanufactured Brick: Bricks Without Clay or Carbon (via Beyond the Beyond) Previously:Best Buy allegedly sells brick in a box ... again How To: build the ultimate, cheap home pizza oven Read the rest
The suit was brought by the ACLU and the Public Patent Foundation, who argued that US Patent and Trademark Office was wrong to grant patents on genes, as these are not patentable subject matter. The judge agreed, saying that gene patents are patents on a "law of nature" and called the isolation of genes and filing patents on them "a lawyer's trick that circumvents the prohibition on the direct patenting of the DNA in our bodies but which, in practice, reaches the same result."
Which sounds to me like a precedent against all patents that rely on isolated genes. Of course, this isn't over: the pharma/biotech stalwarts interviewed in the linked NYT piece are talking appeal, and I'm sure they'll try to go all the way to the Supreme Court.
I think that the problem here is in the untested idea that imparting exclusive rights to the genome will incentivize more research than allowing anyone to build on discoveries in the genome. It's clear that some exclusive rights provide an incentive so some people to do work. But these exclusive rights also scare off people who have good ideas but are worried about being bankrupted by someone who beat them to the patent. Read the rest